SPAGO NANOMEDICAL AKTIEN News | A1J8G8 Nachrichten

❌

Mehr »

Ad hoc-Mitteilungen:

Freitag, 27.06.2025 - Börsentäglich über 12.000 News

Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche

Aktien»SPAGO NANOMEDICAL AKTIE»News

Branche

Biotechnologie

Aktienmarkt

Sonstige

1-Jahres-Chart

5-Tage-Chart

Alle
Pressemitteilungen
Empfehlungen
Chartanalysen
Berichte

Zeit	Aktuelle Nachrichten Sprache: Alle DE EN	Leser	Medien
03.06.	Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation	206	ACCESS Newswire	LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing... ► Artikel lesen
14.05.	Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB	205	ACCESS Newswire	LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the AGM... ► Artikel lesen
07.05.	Spago Nanomedical Interim Report January-March, 2025	229	ACCESS Newswire	LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 338 (KSEK 350)The loss for the quarter amounted... ► Artikel lesen
15.04.	Spago Nanomedical Publishes The Annual Report for 2024	252	ACCESS Newswire	LUND, SE / ACCESS Newswire / April 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2024 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen
09.04.	Notice To Annual General Meeting of Spago Nanomedical AB	292	ACCESS Newswire	LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version... ► Artikel lesen
	SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln
04.04.	Spago on the increased dose in Tumorad-01	2	Cision News
20.03.	Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical's Board	600	ACCESS Newswire	LUND, SE / ACCESS Newswire / March 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board... ► Artikel lesen
06.03.	Spago takes Tumorad-01 study to the next level	1	Cision News
04.03.	Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01	300	ACCESS Newswire	LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose... ► Artikel lesen
06.02.	Spago Nanomedical year-end report January-December, 2024	251	ACCESS Newswire	LUND, SE / ACCESS Newswire / February 6, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 617 (KSEK 731)The loss for the quarter... ► Artikel lesen
15.01.	Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology	228	ACCESS Newswire	LUND, SWEDEN / ACCESSWIRE / January 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that a manuscript on product candidate pegfosimer manganese has... ► Artikel lesen
18.12.24	Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01	382	ACCESS Newswire	LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according... ► Artikel lesen
06.11.24	Spago Nanomedical Interim Report January-September 2024	266	ACCESS Newswire	LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad programJULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 485 (KSEK... ► Artikel lesen
21.10.24	Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2025	265	ACCESS Newswire	LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen
01.10.24	Spago Nanomedical in New Phase with Full Focus on the Tumorad Program	336	ACCESS Newswire	LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB (publ) has decided that the company's resources will be focused... ► Artikel lesen
27.08.24	Spago Nanomedical's Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group	374	ACCESS Newswire	LUND, SE / ACCESSWIRE / August 27, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that the independent Data Monitoring Committee (DMC) recommends to proceed... ► Artikel lesen
21.08.24	Spago Nanomedical Interim Report January-June 2024	396	ACCESS Newswire	LUND, SE / ACCESSWIRE / August 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Clinical and non-clinical progress in the Tumorad program APRIL - JUNE IN BRIEFNet sales for the quarter amounted... ► Artikel lesen

17 Nachrichten in den letzten 12 Monaten

Unternehmen / Aktien	Aktienkurs	%	Top-Nachrichten
QIAGEN	41,230	+2,74 %	Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €)	Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen
VOR BIOPHARMA	0,890	0,00 %	Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics	BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16. Worthington... ► Artikel lesen
TARSUS PHARMACEUTICALS	40,330	+0,40 %	Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements	Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen
SPRINGWORKS THERAPEUTICS	46,990	+0,04 %	SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors	- If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors - - Decision from European Commission expected in the third... ► Artikel lesen
VERVE THERAPEUTICS	11,255	0,00 %	BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab
EVOTEC	7,196	+0,50 %	Evotec-Aktie: Kurs legt zu (6,734 €)	Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen
BIONTECH	90,80	+0,17 %	BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung	Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen
RECURSION PHARMACEUTICALS	5,410	0,00 %	Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update	Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen
ADMA BIOLOGICS	18,380	+4,43 %	ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
KYMERA THERAPEUTICS	45,720	0,00 %	Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders	FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen
ITEOS THERAPEUTICS	10,020	-0,20 %	iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations	- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen
PHATHOM PHARMACEUTICALS	9,550	0,00 %	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen
KEROS THERAPEUTICS	13,510	-1,31 %	Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders	LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen
EDGEWISE THERAPEUTICS	13,050	0,00 %	Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies	- New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen
SUMMIT THERAPEUTICS	21,310	0,00 %	H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target

Das Unternehmen SPAGO NANOMEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -9,79 % bei einem Aktienkurs von 0,026 Euro.

VerkaufenHaltenKaufen

■ Verkaufen

■ Halten

■ Kaufen

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .

Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.

SPAGO NANOMEDICAL AB

Aktuelle News zur SPAGO NANOMEDICAL Aktie

Aktuelle Kennzahlen zu SPAGO NANOMEDICAL